Search results for "Combination"

showing 10 items of 1379 documents

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct

The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients

2012

Abstract OBJECTIVES: The aim of this study was to evaluate the opioid response in patients receiving morphine and pregabalin, independently from the presumed pain mechanisms, in comparison with patients receiving morphine treatment only. METHODS: A multicenter prospective randomized controlled study was carried out in a sample of 70 advanced cancer patients with pain requiring strong opioids. Thirty-five patients (group MO) were randomized to receive sustained-release morphine using initial doses of 60 mg/day. Thirty-five patients (group MO-PR) were randomized to start the same morphine doses and pregabalin in increasing doses, starting with 25 mg/day up to 150 mg/day in one week. The follo…

Malecancer painAnalgesicPregabalinPregabalinPainSettore MED/42 - Igiene Generale E Applicatalaw.inventionDose-Response Relationshipadvanced cancer patientDrug TherapyQuality of lifeRandomized controlled triallawassessment toolsNeoplasmsmedicineHumansDrug Interactionslow doses pregabalinBrief Pain Inventorygamma-Aminobutyric AcidPain Measurementneuropathic painAnalgesicsDose-Response Relationship DrugMorphinebusiness.industryassessment tools; cancer pain; neuropathic pain; opioid response; Analgesics; Dose-Response Relationship Drug; Drug Interactions; Drug Therapy Combination; Female; Humans; Italy; Male; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Pregabalin; Treatment Outcome; gamma-Aminobutyric Acid; Anesthesiology and Pain Medicine; Neurology (clinical)Palliative CareAdvanced cancerTreatment OutcomeAnesthesiology and Pain MedicineItalyOpioidlow doses pregabalin; advanced cancer patients; epidemiologic studyopioid responseAnesthesiaCombinationepidemiologic studyMorphineDrug Therapy CombinationFemaleNeurology (clinical)Drugbusinessmedicine.drug
researchProduct

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

2006

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough pain in cancer patients. The intravenous route has been proven to be safe and effective, providing rapid analgesia in patients receiving oral morphine. Transdermal buprenorphine (TTS-BUP) is increasingly used in cancer pain management, but this drug has been labeled as a difficult drug to use in combination with other opioids. The aim of this open-label study was to verify the safety and effectiveness of intravenous morphine (IV-MO) for the treatment of episodic pain in cancer patients receiving TTS-BUP. A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable bas…

Malecancer painPalliative careExacerbationtransdermal buprenorphinePainOpioidAdministration CutaneousInjectionsNeoplasmsmedicineSecondary PreventionHumansepisodic breakthrough painDosingAdverse effectbreakthrough pain; cancer pain; Intravenous morphine; opioids; transdermal buprenorphine; Administration Cutaneous; Analgesics Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections Intravenous; Male; Middle Aged; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Secondary Prevention; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Nursing (all)2901 Nursing (miscellaneous)General NursingPain MeasurementAnalgesicsMorphinebusiness.industryPalliative CareopioidsIntravenous morphineMiddle Agedbreakthrough painBuprenorphineAnalgesics Opioidtransdermal buprenorphine.Drug CombinationsCutaneousAnesthesiology and Pain MedicineTreatment OutcomeNeurologyOpioidAnesthesiaAdministrationInjections IntravenousMorphineFemaleNeurology (clinical)IntravenousCancer painbusinesssafety and effectiveness of intravenous morphinemedicine.drugBuprenorphineJournal of pain and symptom management
researchProduct

Acute renal insufficiency and pancreatitis in a child with atypical Henoch–Schönlein purpura: efficacy of a single dose of cyclophosphamide

2018

A 9-year-old boy with petechiae on the legs and abdominal pain was unsuccessfully treated with steroids. He was admitted to our hospital for the onset of fever, ecchymosis, and arthralgia. Skin lesions suggested vasculitis, but they were not typical of Henoch–Schönlein purpura. He showed ecchymosis of the scrotal bursa, diffusion of petechiae to the trunk and arms, vomiting, severe abdominal pain, oliguria with hyponatremia, hypoalbuminemia, low C3 levels, high levels of creatinine, blood urea nitrogen, and tubular enzymes, proteinuria, and glycosuria. The urinary sediment showed macrohaematuria, and hyaline and cellular casts. Ultrasound showed polyserositis. He was treated with intraveno…

MalecorticosteroidMedicine (General)medicine.medical_specialtyAbdominal painHenoch-Schonlein purpuraIgA VasculitisEcchymosisAnti-Inflammatory Agentspancreatitisskin lesionCase ReportsMethylprednisoloneBiochemistryGastroenterology03 medical and health sciencesR5-9200302 clinical medicinehemic and lymphatic diseases030225 pediatricsInternal medicinemedicineHumansChildbusiness.industryBiochemistry (medical)pancreatitiAcute renal insufficiencyCell BiologyGeneral MedicineAcute Kidney InjuryPrognosismedicine.diseasePurpuraMethylprednisolonePancreatitisAcute pancreatitisDrug Therapy Combinationcyclophosphamide030211 gastroenterology & hepatologymedicine.symptomHenoch–Schönlein purpuraHyponatremiabusinessImmunosuppressive Agentsmedicine.drugJournal of International Medical Research
researchProduct

Tracking paternal genes with DALP markers in a pseudoarrhenotokous reproductive system: biparental transmission but haplodiploid-like inheritance in …

2000

International audience; The complexity of some sexual reproductive systems in arthropods still leaves both their genetic and epigenetic determinism and their evolutionary significance poorly understood. Pseudoarrhenotoky is characterized by obligate fertilization and differential inactivation and/or elimination of paternal chromosomes in embryos that develop into males. Here, we investigate how the paternal genome is transmitted in a pseudoarrhenotokous mite, Neoseiulus californicus, using codominant genetic markers detected by DALP (direct amplification of length polymorphism). Transmission patterns of parental alleles through one and two generations are reported at four or five loci corre…

MalehaplodiploidyHaploidyBiologyPolymerase Chain ReactionGenomeGenomic Imprinting[SDV.BDD] Life Sciences [q-bio]/Development BiologyGeneticsAnimalsPhytoseiidaeReproductive systemAllele[SDV.BDD]Life Sciences [q-bio]/Development BiologyGeneGenetics (clinical)Recombination GeneticGeneticsMitesObligatepaternal genome lossheterochromatizationPhenotypeGenetic markerpseudoarrhenotokyHaplodiploidyFemaleDALPPloidyacariHeredity
researchProduct

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score An…

2020

INTRODUCTION: Patients with Crohn's disease experiencing endoscopic postoperative recurrence (POR) may benefit from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess the efficacy of anti-TNF in improving mucosal lesions in patients with endoscopic POR. METHODS: Multicenter, retrospective, study of patients with Crohn's disease who underwent therapy with anti-TNF agents for endoscopic POR (Rutgeerts score > i1). Treatment outcomes were assessed by the findings in the last ileocolonoscopy performed after anti-TNF therapy was initiated. Endoscopic improvement and remission were defined as any reduction in the baseline Rutgeerts score and by a R…

Maleintestinal resectionrecurrent diseaseretrospective studyAnti-Inflammatory AgentsLogistic regressionGastroenterologyimmunology0302 clinical medicineCrohn DiseasepreventioncolonoscopyRecurrenceInterquartile rangeadalimumabIntestinal MucosariskCrohn's diseaseazathioprineMercaptopurinedrug effectGastroenterologyclinical trialColonoscopyTNF protein humanfemaleTreatment Outcomemesalazine030220 oncology & carcinogenesisintestine mucosaFemaleDrug Therapy Combination030211 gastroenterology & hepatologydouble-blindantiinflammatory agentImmunosuppressive Agentsmanagementmedicine.drugcombination drug therapyAdultmedicine.medical_specialtyAdolescentdiagnostic imagingtumor necrosis factormercaptopurineArticleYoung Adult03 medical and health sciencesInternal medicinemedicineAdalimumabHumanshumanproceduresPropensity ScoreRetrospective StudiestherapyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabassociationnatural-historyOdds ratioimmunosuppressive agentmedicine.diseaseInfliximabInfliximabConfidence intervalmulticenter studyConcomitantpathologybusiness
researchProduct

Founder-effect speciation theory: Failure of experimental corroboration

1995

The theory of founder-effect speciation proposes that colonization by very few individuals of an empty habitat favors rapid genetic changes and the evolution of a new species. We report here the results obtained in a 10-year-long and large-scale experiment with Drosophila pseudoobscura designed to test the theory. In our experimental protocol, populations are established with variable numbers of very few individuals and allowed to expand greatly for several generations until conditions of severe competition for resources are reached and the population crashes. A few random survivors are then taken to start a new population expansion and thus initiate a new cycle of founding events, populati…

Malemedia_common.quotation_subjectPopulationModels BiologicalCompetition (biology)Drosophila pseudoobscuraGenetic algorithmAnimalseducationCrosses Geneticmedia_commonRecombination Geneticeducation.field_of_studyMultidisciplinarybiologyEcologyReproductionBiological evolutionbiology.organism_classificationNew populationBiological EvolutionGenetics PopulationHabitatDrosophilaFemaleFounder effectResearch Article
researchProduct

Topical allopurinol or corticosteroids and acetylcysteine in the early treatment of experimental corneal alkali burns: a pilot study.

2002

PURPOSE. To investigate the effect of topical allopurinol on experimental corneal burns and to compare this to established treatment modalities such as topical prednisolone and acetylcysteine. METHODS. Twenty Wistar rats were randomly assigned to four groups (n=5 each). The groups were controls (normal saline), allopurinol 0.4% eye drops, prednisolone acetate 1% eye drops and acetylcysteine 8% eyedrops. Corneal burn was induced using a 3 mm paper disc soaked in 1N NaOH for 60 seconds. Drops were instilled 6 times per day. In addition, one drop/day ofloxacine was given to prevent secondary infections. Eyes were enucleated 50 hours later and fixed in 4.5% formaldehyde. Three histological leve…

Malemedicine.drug_classmedicine.medical_treatmentSecondary infectionAdministration TopicalAllopurinolPrednisoloneChemical burnAnti-Inflammatory AgentsAllopurinolPilot Projects030204 cardiovascular system & hematologyAlkalies03 medical and health sciencesCorneal Burn0302 clinical medicineCorneaBurns ChemicalMedicineAnimalsEnzyme InhibitorsRats WistarSalinebusiness.industryEye dropGeneral MedicineFree Radical Scavengersmedicine.diseaseAcetylcysteineRatsOphthalmologyEye Burnsmedicine.anatomical_structureTreatment OutcomeAnesthesia030221 ophthalmology & optometryCorticosteroidDrug Therapy CombinationOphthalmic Solutionsbusinessmedicine.drugEuropean journal of ophthalmology
researchProduct

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

2022

Purpose Only a few studies are available on dose-related effects of sacubitril/valsartan (angiotensin receptor neprilysin inhibition (ARNI)) in real-life patients with heart failure and reduced ejection fraction (HFrEF). We sought to investigate clinical and functional effects in real-life HFrEF patients receiving ARNI at a different cumulative dose. Methods This was an observational study in consecutive outpatients admitted for HFrEF from October 2017 to June 2019. The PARADIGM criteria were needed for enrolment. ARNI was uptitrated according to blood pressure, drug tolerability, renal function and kaliemia. At least 10-month follow-up was required in each patient. Clinical assessment, Kan…

Malemedicine.medical_specialtyARNIBlood PressureWalk TestComorbiditySacubitrilVentricular Function LeftAngiotensin Receptor AntagonistsInternal medicinemedicine6-min walking test Aged Aminobutyrates Angiotensin Receptor Antagonists ARNI Biphenyl Compounds Blood Pressure Comorbidity Dose-Response Relationship Drug Drug Combinations Echocardiography Female Heart failure Humans Left ventricular function Male Middle Aged Prospective Studies Sacubitril/valsartan Stroke Volume Valsartan Ventricular Function Left Walk TestHumansPharmacology (medical)Sacubitril/valsartanProspective Studies6-min walking testAgedPharmacologyHeart FailureEjection fractionDose-Response Relationship DrugCumulative dosebusiness.industryAminobutyratesLeft ventricular functionBiphenyl CompoundsStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseClinical TrialARNI heart failure left ventricular function 6-minutes walking test Sacubitril/valsartan.Drug CombinationsBlood pressureTolerabilityValsartanEchocardiographyHeart failureCardiologyValsartanFemalebusinessSacubitril Valsartanmedicine.drugEuropean journal of clinical pharmacology
researchProduct